PROTACs are fast catching on as an effective modality for drugging previously “undruggable” targets. Designing PROTAC molecules calls for an efficient workflow with assay development and mechanistic studies that help enhance understanding of the structure-activity relationship between the PROTAC, its companion enzyme, and the disease-causing protein to be degraded.
At Syngene, we offer integrated solutions (including tools) to seamlessly move your molecule from Target validation to IND. This includes proof-of-concept (POC) studies to validate whether the target is amenable to the targeted protein degradation (TPD) approach, hit PROTAC degrader identification, lead optimization, and clinical candidate selection. Further, we offer Formulation development services to ensure the bioavailability of your PROTAC compounds.
With 200+ dedicated TPD scientists and more than 15 global clients, we have a strong track record in accelerating PROTAC and X-TAC programs for our clients. Our X-TAC programs cover molecular glues, ribonuclease targeting chimeras (RIBOTACs), lysosome-targeting chimeras (LYTACs), and similar induced proximity approaches for “drugging” undruggable targets.